ClinicalTrials.gg
RecruitingNCT06876259IMAGEUpdated Oct 8, 2026

Artificial Intelligence Diagnostic Decision Support to Reduce Antimicrobial Prescriptions in Young Children With Colds

An interventional study of Standard Clinical Ear Exam and AI app ear exam and diagnosis in Acute Otitis Media (AOM) and Upper Respiratory Infection, sponsored by Timothy Shope. Recruiting at 2 sites in United States. Open to participants aged 6 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Timothy Shope · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 8, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
6 Months to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies in Otitis Media with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Otitis Media · United States.

Planned enrollment
24th of 85
300 · median 119
Started
2025
with 6 others
No phase
40 of 110
7 open now
Primary completion
2027-03
later than 7 of 22 live
Registered
100th of 110
by date

Among the 110 studies in Otitis Media with a site in United States, this one is the 24th largest by planned enrollment of the 85 interventional ones that give a count, is one of 7 that started in 2025, is one of 40 with no phase, reaches primary completion later than 7 of the 22 other live ones, and was the 100th registered.

Otitis Media

244 studies on the registry are indexed under Otitis Media; 34 are open to participants now.

Browse Otitis Media studies →

Open to participants now

12 of the 110 studies in Otitis Media with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Otitis Media studies recruiting now, 5 (25%) set no upper age limit and 15 (75%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: 6 Months to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Otitis Media with a site in United States, or all of them as a file.
02

Study summary

Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.

Read the detailed description

Participants and Setting This will be a 12-month, within-subject design, single center study of 300 children 6 to 24 months of age presenting to their primary care providers at Children's Community Pediatrics offices with upper respiratory symptoms. Exclusion criteria are children with tympanostomy tubes or purulent otorrhea, absence of upper respiratory symptoms, or who are currently taking antimicrobials.

Design and Outcomes

Using a double blind, within-subject design, each child's ear will be assessed by the AI app and a standard clinical exam. The primary outcome measure will be antimicrobial prescription rates derived from 150 paired images that each have an AI app and clinician diagnosis. We will secondarily assess acute otitis media (AOM) diagnosis rates. If the AI app diagnoses AOM it will always prescribe an antimicrobial. Secondary outcomes are described below:

  • Implementation challenges reflected by the proportion of uninterpretable images (cerumen, uncooperative patient, poor technique).
  • Symptom resolution and side effects of antimicrobial use for 10 days after enrollment, regardless of whether children are diagnosed with AOM or prescribed antimicrobials. We will monitor symptoms of AOM daily using a validated symptom scale entered every evening by parents in electronic diaries which we have used in many other studies. If any participant increases their symptom score by >20% at any time, we will contact them and offer a visit. Rates of protocol-defined diarrhea and diaper rash which are the most common side effects of antimicrobial use in this age group will be assessed.
  • AOM recurrences by reviewing the medical record for 3 months following enrollment.

Sample Size Calculation Using paired observations (AI app vs clinician antimicrobial prescription recommendations), an estimated 300 children 6 to 24 months of age presenting to primary care practices with upper respiratory symptoms will need to be enrolled to derive 150 paired interpretable images to detect a 10% difference in AOM diagnosis and subsequent antimicrobial prescription rates between the AI app and clinicians, assuming a power of 80% and two-sided p-value \<0.05. This assumes 15% of children in the target population will truly have AOM, and clinicians will diagnose and treat AOM at a 10% higher rate (25%) compared to the AI app. If clinicians reconcile and follow the app diagnosis and treatment recommendations, this will equate to a 40% reduced/avoidable antimicrobial prescription rate. This estimate accounts for two ears per child and estimates 50% of images will be uninterpretable by the app, and 50% of clinician exams will not result in a diagnosis.

Statistical analysis All analyses will be conducted by a statistician in the General Academic Pediatrics Division, Department of Pediatrics.

The primary outcome of antimicrobial prescription rates will be assessed by the McNemar's Test. Differences in secondary outcomes will be assessed by generalized estimating equation (symptom score) and chi square test (antimicrobial side effects and recurrent AOM).

Descriptive outcomes (uninterpretable images, clinician ability to make a diagnosis, AOM diagnosis, antimicrobial prescriptions) will be reported as rates (%).

Study Procedures:

Screening: Office schedules will be screened to identify children in the eligible age group who are presenting with upper respiratory symptoms.

Consent: Once age-eligible children have checked in to the office their parents will be approached by research personnel to assess their interest in the study and eligibility. Informed consent will be obtained after rooming.

Study Procedures:

The duration of the study procedures, not including standard clinical care, will be about 10 minutes. After consent, each participating child will have two ear exams.

  1. The first exam will be done before the clinician enters the examination room, by study personnel using the AI app (research intervention). The device is a standard otoscope head attached to an iPhone. Only the ear speculum touches the child. The child may be held by the parent or staff either prone or upright. There will be two attempts per ear and attempts will stop at parent request. Study staff may need to remove cerumen (ear wax) using gentle irrigation or curette. Study staff are clinicians experienced in and qualified to remove wax. We expect a significant proportion of unusable images and have accounted for this in our sample size calculation and study flow chart. If there is an uninterpretable image by the app (cerumen, poor image, or poor cooperation) in both ears, the participant will exit the study, and the clinician will be informed before entering the room so that normal care can ensue (cerumen removal for example). If an interpretable image is captured in at least one ear, the diagnosis ("app diagnosis") will be recorded in the data form and blinded to the parents and the clinician. (The app only records a video initially, then the user selects a brief section of the highest quality video to render the diagnosis, which can be done outside of the room).
  2. Study personnel will then step out of the room and the clinician will enter and do the second exam (standard care). (Clinicians may remove cerumen also by irrigation or curette, if necessary, even if the app obtained an interpretable view. Sometimes cerumen can fall into the canal with entry or exit of an exam speculum.) Parents again will be blinded to the clinician's findings - there will be no discussion about the diagnosis or treatment.
  3. The clinician will then step out of the examination room and document a diagnosis ("clinician diagnosis") and treatment decision without consulting the app ("app diagnosis").
  4. The clinician will then view the app video and diagnosis, and then record their "reconciliation diagnosis" and treatment decision.
  5. Clinicians will then reenter the exam room and inform the parents of their diagnosis and treatment.
  6. Clinicians will complete a "final outcome" indicating whether antimicrobials were prescribed and the reason for prescription.

    Data will be recorded in an electronic database.

  7. If participants have a paired image (app and clinician rendered a diagnosis on the same ear) they will complete an AOM symptom score scale (duration: 60 seconds) and instructed how to enter the same symptom score in an electronic diary (duration: two minutes).

Demographic Information:

Research staff will obtain demographic information after the study procedures (duration: 60 seconds).

Follow-up:

All participants will be followed for 10 days to assess symptom resolution and side effects of antimicrobial use. AOM symptoms will be monitored daily for 10 days using a validated symptom scale entered once every evening (duration: 60 seconds), whether on antimicrobial therapy or not, by parents in electronic diaries which have used by our team in many other studies. If any participant increases their symptoms score by >20% at any time, they will be contacted and offered a visit. Rates of protocol-defined diarrhea and diaper rash which are the most common side effects of antimicrobial use in this age group will also be assessed. Finally, AOM recurrences will be monitored by reviewing the electronic medical record for 3 months following enrollment.

Duration:

  1. The app will only be used once, before the clinician exam.
  2. The ear symptom score will be done at the enrollment visit and then for the next 10-11 days in electronic diaries.
  3. Text message reminders to complete the diaries will go for 10-11 days after the enrollment visit.
  4. Medical record review will proceed for 90 days after enrollment.
03

Conditions studied

  • Acute Otitis Media (AOM)
  • Upper Respiratory Infection

Keywords

  • acute otitis media
  • diagnosis
  • artificial intelligence
  • diagnostic classifier
  • antimicrobial stewardship
04

Who can participate

Ages eligible
6 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 6-24 months
  • Presence of upper respiratory infection

Exclusion criteria

Exclusion Criteria:

  • No upper respiratory infection
  • Otorrhea
  • Tympanostomy tubes
  • Currently taking antimicrobials
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    AI App + Standard of care clinical exam

    Using a within subject design, each child's ear will be in the experimental and standard care group. Each ear will be examined by the AI app and a clinician (blinded to the AI app diagnosis) to provide a diagnosis and treatment recommendation.

    Diagnostic Test: Standard Clinical Ear Exam · Diagnostic Test: AI app ear exam and diagnosis

Interventions

  • Diagnostic testStandard Clinical Ear Exam

    The clinician will examine the child's ear with a standard otoscope and give a clinical diagnosis and decision to treat with antibiotics.

  • Diagnostic testAI app ear exam and diagnosis

    Using a standard otoscope with a cell phone mounted to it, research personnel will record a video image of the tympanic membrane and send it to the cloud for analysis using AI enhanced classification software to render a diagnosis and treatment recommendation

06

What researchers measure

Primary outcomes

  1. Antimicrobial prescription rate

    The rate of antimicrobial prescriptions will be compared between standard care and AI app groups.

    Time frame: Day 1

Secondary outcomes

  1. Acute otitis media diagnosis rate

    The rate of diagnosis of acute otitis media will be compared between standard clinical examination and the AI app

    Time frame: Day 1

  2. Uninterpretable image rate

    The rate of AI app and clinician interpretable images among enrolled participants

    Time frame: Day 1

  3. Acute Otitis Media Severity of Symptoms (AOM-SOS) Scale version 6

    A validated and reliable 10-item scale for measuring AOM symptom burden. Responses for each item are scored 0-5 and the total score minimum is 0 and maximum is 50. Higher values represent more severe symptoms.

    Time frame: From enrollment to 11 days after enrollment

  4. Acute otitis media recurrences

    All participants with paired clinician and AI app images in the same ear will be followed for 3 months to assess recurrences of AOM. This will be determined from diagnostic codes entered into the electronic medical record. A new AOM diagnosis must be at least 14 days after the previous diagnosis. AOM recurrences will be expressed as total counts among participants and total counts among ears.

    Time frame: From enrollment to 3 months from enrollment

07

Study locations

2 of 2 sites recruiting
  • Children's Community Pediatrics Brentwood
    Pittsburgh, Pennsylvania 15227, United States
    Recruiting
  • Children's Community Pediatrics Castle Shannon
    Pittsburgh, Pennsylvania 15234, United States
    Recruiting
08

References and documents

Publications

  • Shaikh N, Lee MC, Kurs-Lasky M. Modification of an outcome measure to follow symptoms of children with acute otitis media. Pediatr Res. 2025 Feb;97(2):695-699. doi: 10.1038/s41390-024-03390-2. Epub 2024 Jul 3. PubMed 38961165 ↗
  • Bedard N, Shope T, Hoberman A, Haralam MA, Shaikh N, Kovacevic J, Balram N, Tosic I. Light field otoscope design for 3D in vivo imaging of the middle ear. Biomed Opt Express. 2016 Dec 14;8(1):260-272. doi: 10.1364/BOE.8.000260. eCollection 2017 Jan 1. PubMed 28101416 ↗
  • Shaikh N, Conway SJ, Kovacevic J, Condessa F, Shope TR, Haralam MA, Campese C, Lee MC, Larsson T, Cavdar Z, Hoberman A. Development and Validation of an Automated Classifier to Diagnose Acute Otitis Media in Children. JAMA Pediatr. 2024 Apr 1;178(4):401-407. doi: 10.1001/jamapediatrics.2024.0011. PubMed 38436941 ↗
  • Kuruvilla A, Shaikh N, Hoberman A, Kovacevic J. Automated diagnosis of otitis media: vocabulary and grammar. Int J Biomed Imaging. 2013;2013:327515. doi: 10.1155/2013/327515. Epub 2013 Aug 7. PubMed 23997759 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 15 months after the start.

Of 37 non-industry interventional studies with no phase under Otitis Media, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 64. This study's planned 15 months is below that.

Counting every sponsor, half of 46 studies reached it within 38 months; a quarter within 13 and three quarters within 51.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Mar 2027, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 14, 2025
StartActual
Dec 4, 2025
Primary completionEst.
Mar 30, 2027was Dec 2026
CompletionEst.
Jul 1, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 30, 2026→Mar 30, 2027
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Dec 30, 2026→Mar 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06876259
Lead sponsor
Timothy Shope
Responsible party
Timothy Shope (Professor of Pediatrics, University of Pittsburgh) — Sponsor-investigator
First posted
Mar 14, 2025
Start date
Dec 4, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Timothy R Shope, MD, MPH
Contact
timothy.shope@chp.edu
412-692-5471
Nader Shaikh, MD, MPH
Contact
nader.shaikh@chp.edu
412-996-2653
Timothy R Shope, MD, MPH
principal investigator · UPMC Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion